ACLY and autoimmune polyendocrinopathy: The findings indicate that patients with arterial APS or triple positivity (anti-cardiolipin (aCL), anti-β2 glycoprotein I (β2GPI), and lupus anticoagulant (LAC)) should be treated with VKA, whereas those with venous APS and single or double positivity may be candidates for NOACs.